U.S. AI-Enabled Prosthetics and Orthotics Market 17.2% CAGR

Market Outlook

The U.S. AI-Enabled Prosthetics and Orthotics Market was valued at USD 1.38 billion in 2026 and is projected to reach USD 3.58 billion by 2032, expanding at a CAGR of 17.20% during the forecast period 2027–2032. Historical market analysis covers 2023 to 2025, when the market expanded from USD 0.92 billion in 2023 to USD 1.05 billion in 2024 and USD 1.19 billion in 2025. Values in this report are expressed in USD billions.

The market is entering a structurally different phase from the conventional U.S. prosthetics and orthotics industry. Revenue growth is shifting toward prosthetic knees and feet with real-time sensor feedback, myoelectric upper-limb systems with machine-learning-based intent recognition, adaptive neuro-orthoses, powered braces, sensor-integrated sockets, digital fitting systems, and wearable robotic mobility technologies. Artificial intelligence in this market does not function as a standalone software layer. Its commercial value is created when algorithms convert gait, load, muscle-signal, movement, terrain, or socket-interface data into immediate device behavior that improves stability, mobility, control, comfort, safety, or clinical decision-making.

The U.S. patient pool creates a durable clinical foundation for this transition. More than 2.3 million Americans are living with limb loss, while lower-limb amputations represent the dominant share of acquired limb loss. At the same time, diabetes, peripheral artery disease, neurological impairment, spinal cord injury, stroke, age-related mobility loss, and musculoskeletal weakness create a much larger population that can benefit from intelligent orthotic and wearable assistive systems. AI-enabled technologies are therefore expanding the addressable market beyond traditional amputee care into neurorehabilitation, mobility restoration, fall prevention, and long-term functional assistance.

Commercial adoption is also becoming less dependent on technology novelty and more dependent on demonstrable clinical economics. U.S. prosthetists, rehabilitation physicians, health systems, rehabilitation hospitals, Veterans Affairs facilities, and payers increasingly evaluate intelligent devices through functional improvement, fall-risk reduction, energy expenditure, patient adherence, activity levels, device utilization, clinician programming burden, durability, reimbursement eligibility, and the frequency of follow-up adjustments. This favors platforms that combine advanced hardware with measurable patient data and longitudinal clinical support.

The forecast trajectory reflects continued penetration of microprocessor-controlled lower-limb systems, broader access among Medicare beneficiaries, accelerating use of pattern recognition in upper-limb prosthetics, commercialization of powered orthoses, improving reimbursement for robotic exoskeletons, expansion of connected O&P care, and the emergence of sensor-rich prosthetic interfaces. The market is projected at USD 1.62 billion in 2027, USD 1.90 billion in 2028, USD 2.22 billion in 2029, USD 2.60 billion in 2030, USD 3.05 billion in 2031, and USD 3.58 billion by 2032.

Introduction

According to the U.S. AI-Enabled Prosthetics and Orthotics Market Report, the industry sits at the intersection of medical devices, rehabilitation technology, robotics, human-machine interfaces, biomechanics, machine learning, and digitally connected clinical care. Unlike conventional prostheses and orthoses that primarily provide structural support or mechanical replacement, intelligent systems continuously interpret physical or physiological signals and modify device behavior in response.

The underlying clinical need is substantial. Limb loss remains closely linked with vascular disease, diabetes, trauma, infection, cancer, and congenital limb difference. The U.S. also has a much broader mobility-impaired population. Difficulty walking or climbing steps affects a significant portion of adults, while stroke, spinal cord injury, neurological disorders, and age-related weakness create continuing demand for orthotic control, powered assistance, gait training, and mobility restoration.

Lower-limb prosthetics represent the most commercially mature AI-enabled category. Microprocessor knees already use electronic sensors and control logic to respond to gait phase, walking speed, stance conditions, slopes, stairs, and stumble events. More advanced systems are moving toward integrated knee-foot coordination, powered flexion and extension, adaptive terrain response, connected programming, activity tracking, and individualized gait profiles.

Upper-limb prosthetics are progressing through a different innovation pathway. Myoelectric hands and arms increasingly use multi-channel electromyographic signals, pattern-recognition algorithms, proportional control, app-based configuration, sensory feedback, and machine learning to decode user intent. The commercial challenge is no longer simply producing additional grip patterns. Manufacturers must reduce cognitive burden, shorten training requirements, improve signal reliability, withstand daily use, and provide intuitive switching between functions.

Orthotics are also becoming more intelligent. Microprocessor-controlled stance and swing systems, powered elbow or arm orthoses, functional electrical stimulation, wearable robotic braces, and sensor-driven neuro-orthotic technologies are converting traditionally passive support products into dynamic therapeutic systems. The resulting market is increasingly connected to rehabilitation medicine, neurology, stroke recovery, spinal cord injury treatment, and home-based mobility.

Key Market Drivers: What’s Fueling the U.S. AI-Enabled Prosthetics and Orthotics Market Boom?

The first major driver is the size and changing composition of the U.S. limb-loss population. More than two million Americans live with acquired limb loss, with lower extremity loss substantially more common than major upper extremity loss. Vascular disease and diabetes remain central drivers of lower-limb amputation, creating a patient population that is frequently older and medically complex. For intelligent prosthetic manufacturers, this is strategically important because future growth cannot rely only on young, high-activity amputees. Commercial scale increasingly depends on technologies that demonstrate value among moderate-activity users, older Medicare beneficiaries, and patients at elevated risk of falls.

Diabetes provides an especially important demand anchor. U.S. hospital data have recorded approximately 166,000 lower-extremity amputation hospitalizations among adults with diabetes in a single year. This level of clinical burden supports recurrent requirements for prosthetic fitting, replacement sockets, component upgrades, rehabilitation, gait training, and long-term O&P management.

The second driver is expanding reimbursement access to advanced lower-limb technology. Medicare policy has moved toward broader access to fluid, pneumatic, and electronic or microprocessor-controlled knees for selected K2 beneficiaries when documentation demonstrates functional need, safety benefit, and suitability. Historically, advanced microprocessor technology was concentrated heavily among higher-functioning K3 and K4 users. The ability to serve qualifying K2 patients significantly enlarges the commercially addressable Medicare population and encourages manufacturers to develop intelligent products around stability, stumble recovery, simpler operation, and everyday activities rather than athletic performance alone.

The third driver is growing clinical acceptance of machine-learning-based upper-limb control. Pattern recognition can interpret multiple residual muscle-signal patterns and translate them into intended hand, wrist, or arm movement. The introduction of a dedicated U.S. HCPCS pathway for upper-extremity pattern-recognition decoding strengthens commercialization because billing can more clearly distinguish advanced control technology from conventional dual-site myoelectric control.

The fourth driver is the large U.S. mobility-impairment population. Mobility disability is among the most common disability categories in the country, while difficulty walking or climbing steps affects a meaningful share of adults. This expands the addressable opportunity for intelligent orthoses beyond amputation care. Stroke survivors, people with neurological weakness, individuals with spinal cord injury, and patients with progressive or chronic mobility limitations increasingly represent potential users of powered braces, FES-based neuro-orthotics, robotic gait systems, and assistive exoskeletons.

The fifth driver is improving economic support for wearable robotic systems. Historically, personal exoskeleton adoption was constrained by high acquisition cost and inconsistent payer coverage. Medicare’s recognition of personal exoskeletons within the brace benefit category and establishment of a substantial purchase payment level improved the commercial pathway. This does not eliminate medical-necessity requirements, but it creates a more credible reimbursement framework for manufacturers, rehabilitation specialists, and patients.

The sixth driver is the maturation of the U.S. O&P delivery infrastructure. The country has thousands of accredited O&P facilities, national clinical networks, specialized upper- and lower-extremity programs, academic O&P schools, VA prosthetic services, rehabilitation hospitals, and highly trained certified practitioners. Large clinical networks are particularly important because AI-enabled devices require fitting, programming, patient training, software updates, troubleshooting, outcomes documentation, and periodic adjustment. A sophisticated distribution and clinical-support network therefore acts as a competitive barrier as well as a market-growth enabler.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation is shifting from electronic control toward context-aware mobility. Earlier generations of microprocessor prostheses focused primarily on recognizing gait phase and adjusting hydraulic resistance. Newer systems combine inertial measurement, load sensing, joint-angle data, cadence detection, slope recognition, stumble recovery, activity monitoring, user modes, app connectivity, and increasingly powered assistance.

Lower-limb systems are becoming more integrated. Rather than allowing a prosthetic knee and ankle to function as independent components, advanced systems coordinate information across joints. This matters because biological walking depends on continuous interaction among the hip, knee, ankle, terrain, and center of mass. Integrated control can improve transitions between level walking, slopes, stairs, standing, sitting, and variable cadence.

Powered knees are expanding the functional ceiling. Conventional microprocessor knees regulate resistance but do not replace all of the positive mechanical work created by biological muscles. Powered systems can actively assist flexion or extension, making stair climbing, sit-to-stand movement, ramp navigation, and other high-demand activities more achievable. Artificial intelligence and adaptive sensing determine when assistance is required and how much power should be applied.

Upper-limb innovation is increasingly concentrated on intuitive intent decoding. Conventional myoelectric prostheses may require sequential switching or deliberate muscle contractions that add cognitive burden. Pattern-recognition systems learn the distinct combinations of residual muscle activity associated with intended movements. This allows a broader set of commands to be controlled through more natural muscle activation. Emerging systems add artificial-intelligence coaching, app-based retraining, wireless electrodes, grip personalization, and sensory feedback.

Socket intelligence is another emerging competitive frontier. Socket comfort remains one of the most important determinants of prosthesis acceptance because residual-limb volume changes, pressure concentration, heat, shear, alignment, and tissue tolerance influence whether a technologically advanced limb is actually worn. Sensor-integrated sockets and liners can generate real-time information about limb-interface conditions. The long-term opportunity is to convert these measurements into earlier clinical intervention, automated fit adjustment, predictive maintenance, and evidence-based socket replacement.

Neuro-orthotics are evolving through combinations of sensors, FES, powered actuation, and adaptive control. Devices can increasingly respond to gait events or movement intent instead of providing constant passive resistance. This improves relevance in foot drop, neuromuscular weakness, stroke rehabilitation, and other neurological conditions where timing is as important as structural support.

Finally, the innovation cycle is expanding toward neural interfaces. Implanted or non-invasive interfaces that decode peripheral nerve or muscle activity could ultimately make prostheses feel less like externally commanded tools and more like extensions of the user. Commercial adoption remains earlier-stage than microprocessor knees or myoelectric pattern recognition, but investment activity shows that major manufacturers view human-machine interfaces as strategically important to the next generation of prosthetic control.

Segmentation Insights

The U.S. AI-Enabled Prosthetics and Orthotics Market is segmented on the basis of product type, technology, application, end user, payer and reimbursement channel, and region.

By Product Type

AI-Enabled Lower-Limb Prosthetics

AI-enabled lower-limb prosthetics represented USD 0.57 billion in 2026, accounting for approximately 41.3% of market revenue and making this the largest product category. The segment includes microprocessor knees, powered knees, sensor-enabled feet and ankles, integrated knee-ankle systems, intelligent control modules, and connected lower-limb components.

Demand is anchored by the predominance of lower-limb loss in the U.S. and by the clinical consequences of falls, instability, uneven terrain, and high energy expenditure among transfemoral amputees. Medicare’s broader access pathway for qualifying K2 users expands the addressable population beyond the traditional K3/K4 base. Intelligent knees with stumble recovery, real-time stance and swing control, adaptive resistance, connected programming, and terrain-responsive features should therefore capture an increasing share of premium lower-limb prescriptions. The segment is projected to expand at approximately 16.2% annually through 2032.

AI-Enabled Upper-Limb and Bionic Prosthetics

AI-enabled upper-limb systems generated USD 0.22 billion in 2026, representing approximately 15.9% of the market. Products include multi-articulating bionic hands, externally powered arms, sensorized terminal devices, myoelectric wrists, machine-learning control modules, sensory-feedback systems, and app-connected prosthetic interfaces.

Although major upper-limb amputation affects a smaller population than lower-limb loss, average technology intensity can be high. The commercial value pool is moving from the hand itself toward an integrated control ecosystem including EMG acquisition, machine-learning intent recognition, wrist positioning, grip selection, sensory feedback, software, and training. The establishment of a dedicated pattern-recognition HCPCS pathway improves the reimbursement environment for advanced control systems. With ongoing launches of faster, lighter, waterproof, more durable, and more intuitive hands, this segment is expected to grow at approximately 18.5% annually through 2032.

Smart Orthotic and Neuro-Orthotic Systems

Smart orthotic and neuro-orthotic devices accounted for USD 0.36 billion in 2026, or approximately 26.1% of market revenue. The category includes microprocessor-controlled knee-ankle-foot orthoses, powered upper-extremity orthoses, adaptive bracing, sensor-based gait systems, FES-enabled devices, and digitally programmed neuro-orthotic platforms.

The addressable population extends far beyond limb loss. More than one in four U.S. adults has some form of disability, and mobility limitation is a major component of the national disability burden. Orthotic intelligence is particularly valuable where a patient’s functional state changes during the gait cycle and a fixed mechanical brace cannot provide the optimum balance between stability and mobility. Stroke, multiple sclerosis, spinal cord injury, post-polio weakness, peripheral nerve injury, and other neurological conditions are important clinical targets. The segment is forecast to expand at approximately 16.7% annually.

Powered Exoskeletons and Hybrid Assistive Systems

Powered exoskeletons and hybrid assistive systems contributed USD 0.23 billion in 2026, representing approximately 16.7% of market revenue. The segment includes personal walking exoskeletons, rehabilitation exoskeletons, self-balancing systems, wearable robotic lower-limb devices, and hybrid assistive mobility platforms positioned within rehabilitation or orthotic care.

This category has one of the highest technology barriers but also one of the strongest long-term expansion profiles. FDA-cleared systems are increasingly moving from specialized rehabilitation laboratories toward clinical rehabilitation networks and, selectively, personal use. Medicare recognition of qualifying personal exoskeletons within the brace benefit framework materially improves market viability. The category is projected to grow at approximately 19.0% annually through 2032.

By Technology

Microprocessor Control and Sensor Fusion

Microprocessor control and multi-sensor fusion represented USD 0.53 billion in 2026. This is the market’s most mature intelligence architecture and dominates lower-limb prosthetics. Modern systems use combinations of load sensors, joint-angle measurements, inertial measurement units, cadence detection, pressure signals, and movement data to adjust resistance or operating mode in real time.

The critical commercial shift is from predefined programming toward continuous adaptation. Clinicians increasingly value systems that can support multiple activity levels, recognize changes in terrain, improve stumble response, record activity, and simplify fine-tuning.

Myoelectric Machine Learning and Pattern Recognition

Myoelectric and pattern-recognition technologies generated USD 0.22 billion in 2026. These systems acquire electrical activity from residual muscles and use classification algorithms to identify intended movement. Pattern-recognition control is particularly important in multi-function upper-limb prostheses because it can reduce dependence on sequential switching between grips.

The technology received an important commercial boost from the creation of HCPCS L6700 for upper-extremity myoelectronic control with additional EMG inputs and pattern-recognition decoding. This gives providers a clearer reimbursement framework and should increase adoption in specialized upper-limb programs.

Adaptive Powered Actuation and Wearable Robotics

Adaptive powered actuation accounted for USD 0.38 billion in 2026. It includes powered prosthetic knees, powered orthoses, rehabilitation exoskeletons, personal exoskeletons, robotic gait devices, and motor-assisted components.

Unlike passive or resistance-controlled systems, these technologies contribute mechanical power. Sensors and software determine when assistance should occur, while motors or other actuators execute the movement. The segment benefits from improving batteries, motor efficiency, torque density, balance algorithms, and control software.

Connected Software, Digital Tuning and Remote Analytics

Connected programming, telemetry, remote configuration, and digital analytics represented USD 0.16 billion in 2026. Mobile apps increasingly allow clinicians to configure devices, adjust modes, review activity, update firmware, and support patients without relying exclusively on hardware changes.

The economic value lies in reducing programming time and improving continuity of care. For large O&P networks, digital tools may also support standardization across clinicians and locations. Longer term, longitudinal device data can strengthen outcomes evidence required by payers.

Neural and Advanced Human-Machine Interfaces

Neural-interface and advanced intent-decoding technologies accounted for USD 0.09 billion in 2026. This category remains smaller but represents a strategically important frontier. Peripheral nerve interfaces, advanced implanted sensors, improved EMG acquisition, and AI-based signal decoding aim to create more intuitive prosthetic control.

Commercial penetration remains constrained by regulatory complexity, surgical requirements for some technologies, long clinical-development cycles, and the need to demonstrate meaningful improvement over modern non-invasive control. Even so, strategic investment by established prosthetic manufacturers indicates that neural interfaces are moving closer to mainstream development pipelines.

By Application

Dysvascular and Diabetes-Related Limb Loss

Dysvascular and diabetes-related applications represented USD 0.43 billion in 2026, making them the largest clinical application. Diabetes-related lower-extremity complications remain a major source of U.S. amputations; hospital data have recorded roughly 166,000 lower-extremity amputation discharges among adults with diabetes in a year.

This population is highly relevant to AI-enabled prosthetics because many patients are older, have balance limitations, contralateral limb disease, neuropathy, cardiovascular comorbidity, or limited endurance. Advanced knees and feet must therefore create measurable safety and stability benefits rather than simply supporting high activity.

Trauma and Congenital Limb Difference

Trauma and congenital limb difference accounted for USD 0.29 billion in 2026. These patients include working-age traumatic amputees, veterans, occupational-injury patients, motor-vehicle trauma survivors, pediatric users, and individuals born with limb differences.

The segment has disproportionately high adoption of premium upper-limb bionic technology because younger and working-age users often prioritize function across employment, household activity, recreation, and social participation. Durable hands, intuitive pattern recognition, waterproofing, sensory feedback, and low-weight designs are important differentiators.

Stroke and Neurological Mobility Impairment

Stroke and other neurological mobility conditions generated USD 0.27 billion in 2026. In 2024, 5.0% of U.S. adults aged 45 and older reported having previously experienced a stroke, and prevalence was higher among older and nonmetropolitan populations.

AI-enabled orthoses, powered arm supports, robotic gait devices, FES systems, and rehabilitation exoskeletons can address weakness, foot drop, asymmetric gait, impaired motor control, and reduced endurance. The opportunity is expanding as rehabilitation providers seek technologies that generate repeatable movement while producing objective patient-performance data.

Spinal Cord Injury and Paralysis

Spinal cord injury and paralysis applications represented USD 0.19 billion in 2026. This is a smaller population but one of the highest-value technology applications because powered exoskeletons require sophisticated actuation, balance control, safety systems, training, and support.

FDA clearances for new personal and rehabilitation exoskeleton platforms, together with reimbursement progress, are moving the category toward broader commercialization. The most important commercial determinant will be the conversion of successful clinical demonstrations into consistent payer authorization and sustainable personal-use economics.

Musculoskeletal, Geriatric and Other Mobility Applications

Musculoskeletal, geriatric, and other mobility applications accounted for USD 0.20 billion in 2026. The U.S. mobility burden is much larger than the amputee population alone, with 18.2% of adults reporting some difficulty walking or climbing steps in 2024.

This supports demand for intelligent orthotic devices that can stabilize joints, assist movement, compensate for muscle weakness, or reduce fall risk. Population aging will make this segment strategically important, particularly where devices demonstrate the ability to preserve independent living and reduce downstream care costs.

By End User

Orthotic and Prosthetic Clinics

Independent and national O&P clinics generated USD 0.73 billion in 2026, accounting for more than half of market revenue. These clinics remain the principal channel for prescription fulfillment, fitting, alignment, gait optimization, socket fabrication, device programming, training, follow-up, and reimbursement documentation.

The U.S. has thousands of accredited O&P facilities. Hanger Clinic alone operates more than 925 patient-care locations with approximately 1,800 certified clinical providers and treats around one million patients annually. This national infrastructure is highly relevant to AI-enabled devices because adoption requires clinicians who can evaluate functional level, justify advanced technology, configure electronics, train users, and document outcomes.

Hospitals and Inpatient Rehabilitation Centers

Hospitals and rehabilitation centers represented USD 0.25 billion in 2026. Their role is strongest in acute amputation care, inpatient rehabilitation, stroke recovery, spinal cord injury rehabilitation, complex neurological care, and robotic gait training.

These institutions are important early adopters of wearable robotics and advanced orthoses because they have multidisciplinary rehabilitation teams and sufficient patient volumes to justify capital-intensive technologies. Academic hospitals also influence product adoption through clinical trials and evidence generation.

Veterans Affairs and Military Care

VA and military channels accounted for USD 0.17 billion in 2026. The Department of Veterans Affairs operates one of the most comprehensive prosthetic-service ecosystems in the country. In fiscal 2025, VA reported providing more than 24.5 million prosthetic devices, items, and services to 3.6 million Veterans, although this broad category includes substantially more than artificial limbs.

The VA remains strategically important for advanced prosthetic limbs, upper-extremity technologies, powered mobility, specialty rehabilitation, and innovation evaluation. Veteran populations have historically played an important role in driving development of high-function prosthetics and novel human-machine interfaces.

Home, Community and Direct-to-Patient Use

Home and community-based utilization represented USD 0.15 billion in 2026. This segment is expanding as devices become more durable, connected, app-configurable, and suitable for daily use outside supervised rehabilitation environments.

Personal exoskeletons, bionic hands, microprocessor knees, powered orthoses, and remote monitoring platforms increasingly derive their value from participation in real-world activities rather than clinic-based performance alone. Manufacturers therefore need service models that support battery management, troubleshooting, updates, repairs, and training after discharge.

Academic, Research and Specialty Centers

Academic and specialty centers represented USD 0.08 billion in 2026. Their direct revenue contribution is smaller, but their influence on technology adoption is disproportionately large. These organizations develop neural interfaces, novel sensors, advanced gait algorithms, osseointegration protocols, robotic control systems, and outcomes methodology that later migrate into commercial products.

By Payer and Reimbursement Channel

Commercial Insurance

Commercial insurance represented USD 0.46 billion in 2026 and remains the largest funding channel by revenue. Employer-sponsored and individual commercial plans are particularly important for working-age traumatic amputees, congenital limb-difference users, and advanced upper-limb systems.

Commercial policies vary materially in medical-necessity criteria, prior authorization, coding interpretation, and documentation requirements. Manufacturers that provide robust clinical evidence and reimbursement support have an advantage over companies relying exclusively on technological differentiation.

Medicare and Medicare Advantage

Medicare and Medicare Advantage represented USD 0.42 billion in 2026. This channel is gaining strategic importance because many patients with dysvascular amputation are older adults.

Expansion of advanced knee coverage for qualifying K2 beneficiaries meaningfully increases the accessible market. At the same time, authorization behavior across Medicare Advantage plans can create significant differences in real-world access, particularly for higher-cost orthotic and robotic systems.

VA, TRICARE and Department of Defense

VA, TRICARE, and defense-related funding accounted for USD 0.23 billion in 2026. This segment has historically supported advanced prosthetic technology, specialized rehabilitation, and complex upper-extremity care.

The channel remains attractive for innovative manufacturers because functional restoration and independence can carry substantial long-term value for injured service members and Veterans. The VA’s national scale also allows technology performance to be observed across a broad clinical network.

Medicaid and State Programs

Medicaid and state-supported programs represented USD 0.17 billion in 2026. Coverage varies by state, creating uneven access to premium technology. Pediatric limb difference, congenital conditions, neurological disability, and low-income adults with acquired limb loss are important patient groups.

State prosthetic-equity initiatives and broader legislative interest in activity-specific prosthetic coverage can gradually increase access, although reimbursement remains more fragmented than Medicare or national VA pathways.

Self-Pay and Other Funding

Self-pay, charitable, workers’ compensation, legal settlement, grants, and other funding sources represented USD 0.10 billion in 2026. This category is especially relevant when patients seek technology beyond payer coverage or when advanced upper-limb devices and specialized activity components face authorization barriers.

Regional Insights: Where the Market is Growing Fastest

The U.S. AI-Enabled Prosthetics and Orthotics Market is geographically segmented into the South, Northeast, West, and Midwest. Regional opportunity differs according to population scale, diabetes prevalence, vascular disease burden, age distribution, trauma volumes, rehabilitation infrastructure, O&P clinic density, academic research presence, VA facilities, insurance mix, state coverage policy, and adoption of advanced medical technology.

The South is the largest regional market in 2026, while the West is expected to record the highest CAGR through 2032. The Northeast remains a high-value clinical and research market, and the Midwest combines a mature O&P delivery network with a strong medical-device and rehabilitation base.

South

The South generated USD 0.52 billion in 2026 and is projected to reach approximately USD 1.39 billion by 2032, expanding at about 17.8% annually. The region includes Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, Texas, and the District of Columbia.

Texas and Florida are the two most commercially important state markets. Texas had approximately 31.7 million residents in 2025, making it the country’s second-most-populous state. Its scale supports high volumes of diabetes management, vascular care, trauma services, O&P fitting, rehabilitation, and veteran care. Houston, Dallas-Fort Worth, Austin, and San Antonio provide concentrated markets for advanced lower-limb prostheses, bionic upper-limb systems, neuro-orthotics, and rehabilitation robotics.

Florida combines a population above 23 million with one of the nation’s largest older-adult populations. More than one-fifth of Floridians are aged 65 or older. This makes Florida structurally important for dysvascular limb loss, Medicare-funded prosthetic care, age-related mobility impairment, orthotic intervention, stroke rehabilitation, and fall-prevention technologies.

North Carolina, Georgia, South Carolina, Tennessee, and Virginia are gaining importance as population growth increases the number of commercially insured and Medicare beneficiaries requiring mobility care. North Carolina and Georgia also have strong academic medical centers and rehabilitation programs capable of adopting advanced technologies. South Carolina, North Carolina, Texas, Tennessee, and Georgia have been among the faster-growing states by population, improving the long-term commercial outlook for O&P providers.

Maryland, Virginia, and the District of Columbia benefit from proximity to major military, federal, research, and rehabilitation institutions. This creates demand for advanced prosthetics, neurotechnology, and clinical trials. Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia have significant chronic-disease and mobility burdens, increasing the clinical need for prosthetic and orthotic intervention even where access to specialist care is more geographically dispersed.

For manufacturers, the South requires a two-track strategy: premium technology penetration through large urban rehabilitation and O&P centers, alongside scalable fitting, tele-support, remote programming, and reimbursement assistance for smaller metropolitan and rural markets.

West

The West accounted for USD 0.31 billion in 2026 and is projected to reach approximately USD 0.85 billion by 2032, representing the fastest regional CAGR of roughly 18.4%. The region includes California, Washington, Oregon, Nevada, Arizona, Utah, Colorado, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the largest Western state opportunity and the country’s most populous state, with more than 39 million residents. Its commercial significance extends beyond population. California combines academic medical centers, VA facilities, advanced rehabilitation hospitals, robotics expertise, digital-health companies, venture funding, engineering talent, and early-adopter provider systems. It is therefore one of the most attractive launch markets for sensorized prosthetics, bionic hands, smart orthoses, AI-enabled gait technologies, and neural-interface research.

Arizona and Nevada benefit from both population growth and older-adult migration, increasing demand for Medicare-funded lower-limb prosthetics and mobility support. Arizona is also relevant to advanced component manufacturing and O&P distribution. Colorado and Utah have sophisticated rehabilitation systems and strong medical-technology ecosystems, supporting premium device adoption.

Washington combines a technology-oriented economy with major health systems and research institutions. Sensor analytics, remote monitoring, digital fabrication, and advanced socket technology are particularly relevant. Oregon also supports connected and patient-centered rehabilitation models.

Idaho, Montana, Wyoming, New Mexico, Alaska, and Hawaii represent smaller absolute markets but create a clear need for remote support because specialty O&P services can require substantial travel. Cloud-enabled programming, digital scanning, tele-rehabilitation, remote activity monitoring, and connected device diagnostics can therefore have greater workflow value in geographically dispersed Western markets.

Northeast

The Northeast generated USD 0.32 billion in 2026 and is projected to reach approximately USD 0.80 billion by 2032, expanding at around 16.4% annually. The region includes Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania.

New York is the largest state market in the region. Its population of approximately 20 million, major academic centers, rehabilitation hospitals, dense specialist base, and large insured population support advanced prosthetic and orthotic adoption. The New York metropolitan area is especially relevant for complex upper-limb care, pediatric limb difference, robotic rehabilitation, and high-acuity neurorehabilitation.

Massachusetts is disproportionately important relative to its population because of its concentration of teaching hospitals, universities, robotics laboratories, biomedical engineering programs, and rehabilitation research. The state is likely to remain a leading early-adoption environment for human-machine interfaces, neural control, advanced sensing, and evidence generation.

Pennsylvania and New Jersey provide large populations and strong rehabilitation infrastructure. Pennsylvania combines major urban markets in Philadelphia and Pittsburgh with extensive regional health systems, while New Jersey benefits from proximity to both New York and Philadelphia healthcare ecosystems.

Connecticut has growing significance through O&P education, clinical care, and fabrication infrastructure. Maine, New Hampshire, Vermont, and Rhode Island are smaller markets, but older populations and rural access issues create demand for connected clinical support and lower-limb mobility technologies.

Procurement in the Northeast tends to be evidence intensive. Academic providers and large payer organizations frequently require stronger clinical-outcome support before adopting expensive technologies. Manufacturers with peer-reviewed evidence, health-economic documentation, clinician training, and clear reimbursement pathways are therefore better positioned than companies competing primarily on engineering specifications.

Midwest

The Midwest represented USD 0.23 billion in 2026 and is projected to reach approximately USD 0.54 billion by 2032, expanding at around 15.3% annually. The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota.

Illinois is a major upper-limb innovation market because of Chicago’s healthcare, research, and prosthetic-technology ecosystem. Machine-learning-based myoelectric control has important commercial roots in the city, strengthening the state’s role in advanced upper-limb prosthetics.

Minnesota remains strategically important because of its medtech manufacturing base, biomedical engineering capabilities, rehabilitation providers, and strong culture of medical-device adoption. Ohio, Michigan, Indiana, and Wisconsin provide established hospital systems, manufacturing employment, trauma care, diabetes-related demand, and large community-based O&P networks.

Missouri, Iowa, Kansas, and Nebraska provide stable demand for lower-limb prosthetics, bracing, and rehabilitation technology. North Dakota and South Dakota are smaller markets but demonstrate the importance of regional referral centers and remote clinical support. Long travel distances make digital scanning, remote programming, and connected monitoring particularly valuable.

The Midwest is likely to grow more slowly than the West or South in percentage terms, but it remains commercially attractive because of durable clinical demand, strong O&P professional networks, medical-device expertise, and comparatively high value placed on evidence-based functionality and service reliability.

Key Market Players

The competitive landscape is fragmented by technology but increasingly concentrated around companies with strong intellectual property, reimbursement expertise, clinical training capabilities, and access to O&P providers. Large prosthetic manufacturers dominate microprocessor knees and advanced lower-limb systems, while smaller technology companies remain influential in AI control, bionic hands, powered orthoses, and wearable robotics.

Competition is shifting from isolated hardware performance toward ecosystems that combine sensing, algorithms, actuation, clinician software, mobile applications, connectivity, training, reimbursement support, and longitudinal outcomes. Companies that can demonstrate real-world improvements in safety, mobility, device utilization, independence, and clinician efficiency will be better positioned to defend premium pricing.

Some of the key players in the U.S. AI-Enabled Prosthetics and Orthotics industry are:

Ottobock North America
Embla Medical / Össur
Blatchford
Hanger, Inc.
PROTEOR USA
Myomo, Inc.
Coapt, LLC
PSYONIC, Inc.
Esper Bionics
Open Bionics
Unlimited Tomorrow
Mobius Bionics
Ekso Bionics
Lifeward Ltd.
Wandercraft

Ottobock and Embla Medical hold strong positions in advanced lower-limb prosthetics and neuro-orthotic technologies. Blatchford and PROTEOR compete through sophisticated microprocessor and integrated lower-limb systems. Hanger has a unique position because its national clinical network influences device evaluation, patient access, outcomes generation, and purchasing behavior.

Coapt is strategically important in machine-learning-based upper-limb intent recognition, while PSYONIC, Esper Bionics, Open Bionics, Unlimited Tomorrow, and Mobius Bionics contribute to innovation in bionic arms and hands. Myomo operates at the intersection of powered orthotics and neuromuscular rehabilitation. Ekso Bionics, Lifeward, and Wandercraft compete in wearable robotic mobility and rehabilitation.

Recent Developments

The U.S. reimbursement environment has become more favorable to intelligent lower-limb prosthetics. Medicare policy expanded eligibility for selected fluid, pneumatic, and electronic or microprocessor-controlled knees to qualifying K2 beneficiaries when functional and medical criteria are documented. This is strategically important because it increases the addressable population for advanced knees beyond traditional higher-activity users and places greater commercial emphasis on stumble recovery, safety, and activities of daily living.

Upper-limb AI control also reached a reimbursement milestone in 2025 with implementation of HCPCS L6700 for upper-extremity myoelectronic control modules using additional EMG inputs and pattern-recognition decoding. A dedicated code gives providers a more standardized pathway for billing machine-learning-based intent control and strengthens the commercial case for advanced upper-limb systems.

Wearable robotic mobility continued to advance. Lifeward received FDA 510(k) clearance for ReWalk 7 in March 2025 and subsequently reported progress obtaining Medicare Advantage and commercial reimbursement. This demonstrates that personal exoskeleton commercialization is moving beyond regulatory clearance toward payer adoption.

The technology frontier advanced further in 2026 when Wandercraft received U.S. clearance for Eve, a personal self-balancing exoskeleton designed for eligible users with spinal cord injury. Self-balancing functionality is an important development because broader personal use depends on reducing reliance on external stabilization and making upright mobility practical during activities of daily living.

Ottobock continued expanding intelligent prosthetic control in 2026. The company introduced a new speedhand solution combining an advanced myoelectric hand, modular wrist options, personalized control, and app-based programming. It also increased investment in human-machine-interface technology and expanded its neuro-orthotics portfolio, reinforcing the industry’s convergence of prosthetics, neural control, software, and intelligent orthotic systems.

The U.S. provider landscape is also consolidating and becoming more data-driven. Hanger announced plans in September 2026 to combine with Numotion, creating a substantially larger mobility and patient-care platform. Separately, Hanger Ventures invested in Prosthetic Fit 360, whose sensor-based technology generates continuous information on residual-limb and socket interaction. These developments highlight the emerging commercial value of data across the entire mobility-care pathway.

Conclusion

The U.S. AI-Enabled Prosthetics and Orthotics Market is positioned to expand from USD 1.38 billion in 2026 to USD 3.58 billion by 2032 at a CAGR of 17.20%. Growth will substantially exceed that of conventional prosthetics and orthotics because value is migrating toward microprocessor control, machine-learning-based intent recognition, powered assistance, connected clinical software, sensor-rich interfaces, wearable robotics, and emerging human-machine interfaces.

AI-enabled lower-limb prosthetics will remain the largest revenue category, supported by a substantial U.S. lower-limb-loss population and broader reimbursement access to advanced knees. Upper-limb bionics should achieve faster growth as machine-learning control, reimbursement coding, improved hand durability, and sensory technologies reduce historical adoption barriers. Intelligent orthotics will expand the addressable market beyond amputees into stroke, neurological weakness, age-related mobility impairment, and rehabilitation. Powered exoskeletons will remain smaller in absolute revenue but represent one of the strongest growth opportunities as FDA clearances and payer pathways mature.

The market will increasingly be defined by clinical economics rather than technical novelty. Manufacturers will need to demonstrate that intelligent devices reduce falls, improve mobility, increase independence, lower energy expenditure, increase device wear time, shorten rehabilitation, or reduce clinician burden. Payers and providers will demand measurable functional improvement alongside sophisticated engineering.

Regionally, the South will remain the largest revenue opportunity because of its population scale, older-adult growth, diabetes burden, and expanding healthcare infrastructure. The West should record the fastest growth due to its technology ecosystem, venture investment, population growth, and early adoption of robotics and connected care. The Northeast will continue to influence national clinical evidence and high-acuity technology adoption, while the Midwest will provide a stable base of O&P expertise, medtech engineering, and mature rehabilitation demand.

For manufacturers, investors, O&P providers, health systems, and technology developers evaluating this market, the central strategic issue is not whether artificial intelligence will enter prosthetic and orthotic care. Intelligent control is already commercially established. The more important questions are which technologies can demonstrate sufficient functional value to justify premium reimbursement, which companies can scale clinician training and patient support, how quickly payer coverage will broaden, and whether device-generated data can become part of routine evidence-based mobility care.

The strongest competitors through 2032 will be those that treat the prosthesis or orthosis not as an isolated mechanical product, but as a connected clinical platform combining advanced hardware, adaptive intelligence, individualized fitting, reimbursement support, measurable outcomes, and long-term patient engagement.